 An empirical model of drug pricing and competition: a dynamic perspectiveRodrigo Refoios Camejo, Clare McGrath and Frans F.H. Rutten International Journal of Economics and Business Research, 2013, vol. 6, issue 2, 173-193 Abstract: In this study we test the impact of competition and other market attributes on the pricing of pharmaceuticals. Three decades worth of market and pricing data were collected and the market for lipid-lowering agents used as a case study. Panel data and cross sectional methods were applied to develop two distinct econometric models: one dynamic longitudinal model continuously following molecules' prices; and one static launch price model considering market conditions at time of launch. The results show a consistent element of price competition reflected both in the launch price of new drugs and in the price observed throughout the molecules' lifecycle. Prices vary greatly depending on market conditions such as the number of competitors, the degree of market concentration, and the existence of generic versions of the molecule. The results also show that a dual competition model is in place with market attributes affecting prices differently depending on the therapeutic proximity of available competitors. Keywords: pharmaceutical pricing; pharmaceutical policy; competition; drug development; lifecycle pricing; pricing regulation; drug pricing; pharmaceutical industry; econometric models; modelling; new drugs. (search for similar items in EconPapers) Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:ids:ijecbr:v:6:y:2013:i:2:p:173-193 Access Statistics for this article More articles in International Journal of Economics and Business Research from Inderscience Enterprises Ltd |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.